Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/28/15
End: 07/31/16
Due: 07/31/17
Phase: N/A
Priority: Normal
Start: 07/21/17
End: 11/02/23
Due: 11/02/24
Phase: N/A
Priority: Normal
Start: 01/24/18
End: 05/08/24
Due: 05/08/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease | NCT02398435 | AB2 Bio Ltd. | user2@example.com | None | 2015-02-28 | 2016-07-31 | 2017-07-31 | - | - | 2025-07-14 |
| Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency | NCT03113760 | AB2 Bio Ltd. | user2@example.com | None | 2017-07-21 | 2023-11-02 | 2024-11-02 | - | - | 2025-07-14 |
| Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension | NCT03512314 | AB2 Bio Ltd. | user2@example.com | None | 2018-01-24 | 2024-05-08 | 2025-05-08 | - | - | 2025-07-14 |